Navigation Links
Lilly Reports Second-Quarter 2011 Results
Date:7/21/2011

(Dollars in millions, except per share data)Three Months EndedSix Months EndedJune 30June 302011(a)2010(b)

% Chg.2011(a)2010(b)

% Chg.Total Revenue

$

6,252.8

$

5,748.7

9%$

12,092.0

$

11,234.2

8%Cost of sales1,228.01,023.9

20%2,408.12,146.4

12%Research and development1,260.61,187.2

6%2,384.62,226.3

7%Marketing, selling and administrative2,043.01,755.4

16%3,828.73,369.8

14%Operating income 1,721.21,782.2

(3)%3,470.63,491.7

(1)%Net interest income (expense)(27.3)(36.5)(57.6)(73.5)Net other income (expense)(30.3)18.1(11.2)129.6Other income  (expense)(57.6)(18.4)

NM(68.8)56.1

NMIncome before income taxes1,663.61,763.8

(6)%3,401.83,547.8

(4)%Income taxes347.7396.9

(12)%711.0883.3

(20)%Net income

$

1,315.9

$

1,366.9

(4)%$

2,690.8

$

2,664.5

1%Earnings per share – basic and diluted

$

1.18

$

1.24

(5)%$

2.42

$

2.41

0%Dividends paid per share

$

.49

$

.49

0%$

.98

$

.98

0%Weighted-average shares outstanding (thousands) – basic1,113,9331,103,7821,112,9601,103,817Weighted-average shares outstanding (thousands) – diluted1,113,9571,103,8071,112,9831,103,843(a)

The second quarter 2011 has been adjusted to eliminate a restructuring charge of $132.3 million (pretax), or $0.11 (after-tax).  The year-to-date 2011 financial statements have been adjusted to eliminate total restructuring charges of $208.6 million (pretax), or $0.17 (after-tax). These charges are related to severance costs from previously announced strategic actions that the company is taking to reduce its cost structure and global workforce. In addition, the first quarter 2011 financial statements have been adjusted to eliminate
'/>"/>

SOURCE Eli Lilly and Company
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16

Related medicine technology :

1. Lilly Presents Follow-Up Data on Semagacestat to Assist Future Alzheimers Disease Research
2. Lilly and Argonne National Laboratory Announce $2 Million Upgrade to Lillys Beamline Capabilities
3. Lilly Donation to Patient Advocate Foundation Expands Services and Access for Patients With Most Common Form of Lung Cancer
4. Lilly CEO Says Biopharmaceuticals Should Be Included in Transatlantic Trade and Economic Discussions
5. Lilly CEO Calls for Improved Dialogue in Germany Between Industry and the Government and Health Care System
6. Lilly Quality Leader Walsh Appointed to Companys Executive Committee
7. Lilly Outlines For Investors How Its Innovation-Based Strategy and Robust Pipeline Will Drive Future Growth Following Upcoming Patent Expirations
8. Lilly Announces New Investment to Further Boost Its Biotechnology Capabilities
9. Lilly Declares Third-Quarter 2011 Dividend
10. Lilly for Better Healthâ„¢ Launches Enhanced Multi-Channel Patient Education Platform
11. Synthes and Lilly Sign Development and Collaboration Agreement
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/3/2015)... -- Biosensors International Group, Ltd. ("Biosensors" or the ... a developer, manufacturer and marketer of innovative medical ... fiscal quarter ended 30 June 2015 ("Q1 FY16"). ... , Biosensors continued to make ... by lower operating expenses and operational improvement. Operating ...
(Date:8/3/2015)... , Aug. 3, 2015 Merrimack Pharmaceuticals, Inc. (Nasdaq: ... host its Second Quarter 2015 Investor Conference Call and ... The call will cover an update on ... quarter 2015 financials. A press release detailing the information ... the afternoon of Monday, August 10. Investors and the ...
(Date:8/3/2015)... , Aug. 3, 2015  Charleston Laboratories, Inc., ... its second clinical development program with a Phase ... CL-H1T contains fast-dissolving promethazine and ... as a treatment for migraine headache pain and ... "Many patients with migraine headaches also suffer from ...
Breaking Medicine Technology:Biosensors Reports Financial Results for the First Quarter of Fiscal Year 2016 2Biosensors Reports Financial Results for the First Quarter of Fiscal Year 2016 3Biosensors Reports Financial Results for the First Quarter of Fiscal Year 2016 4Biosensors Reports Financial Results for the First Quarter of Fiscal Year 2016 5Biosensors Reports Financial Results for the First Quarter of Fiscal Year 2016 6Merrimack Pharmaceuticals Announces Timing of Second Quarter 2015 Investor Conference Call 2Charleston Laboratories, Inc. Initiates Patient Enrollment in a Phase 1 Study of Charleston's Second Product, CL-H1T 2
... 2011 /PRNewswire-Asia-FirstCall/ -- China Sky One Medical, Inc. ("China ... CSKI ), a leading fully integrated pharmaceutical company in ... shareholder letter from Mr. Yanqing Liu, the Company,s Chairman ... full text of this shareholder letter is as follows: ...
... 21, 2011 VIVUS, Inc. (Nasdaq: VVUS ) ... Food and Drug Administration (FDA) for the New Drug Application ... obesity.  The meeting occurred on January 19th at the FDA,s ... the FDA and VIVUS, management and consultants.  At this meeting ...
Cached Medicine Technology:Shareholder Letter from Chairman of China Sky One Medical 2Shareholder Letter from Chairman of China Sky One Medical 3Shareholder Letter from Chairman of China Sky One Medical 4VIVUS Provides Regulatory Update on QNEXA NDA 2VIVUS Provides Regulatory Update on QNEXA NDA 3
(Date:8/3/2015)... Detroit, Mich (PRWEB) , ... August 03, 2015 , ... ... this country has declined, according to a new publication released today by the AAMC ... of black male college graduates over the past three decades, the number of black ...
(Date:8/3/2015)... ... August 03, 2015 , ... The Workgroup for Electronic Data Interchange ... to create efficiencies in healthcare information exchange, announced the release of its findings from ... Human Services (HHS) Secretary, WEDI shared survey results and recommendations , ...
(Date:8/3/2015)... ... ... to an opinion piece published July 28 by the Washington Post, the conventional ... loss may not be accurate. While this system may work for some people, the author ... based both on the individual and at what point that person is in their weight ...
(Date:8/3/2015)... ... August 03, 2015 , ... Bayer has agreed to pay ... claims in which a claimant alleged to have suffered an arterial blood clot including ... control pills, Yaz, Yasmin and Ocella, has been ongoing for well-over five years. In ...
(Date:8/3/2015)... ... August 03, 2015 , ... BESLER Consulting today announced the ... , The MarketingProfs Bright Bulb B2B Awards celebrate the best marketing, communications, and ... launch of their Readmissions Analytics product was selected as one of four finalists ...
Breaking Medicine News(10 mins):Health News:New Publication Focuses on the Decline of Black Males in Medicine 2Health News:New Publication Focuses on the Decline of Black Males in Medicine 3Health News:New Publication Focuses on the Decline of Black Males in Medicine 4Health News:WEDI ICD-10 Survey Results: Industry Nearing Readiness but Physician Practices Lagging Behind 2Health News:WEDI ICD-10 Survey Results: Industry Nearing Readiness but Physician Practices Lagging Behind 3Health News:WEDI ICD-10 Survey Results: Industry Nearing Readiness but Physician Practices Lagging Behind 4Health News:Article Dispelling Weight Loss Myth Correctly Emphasizes the Complicated and Difficult Nature of Weight Loss, Says Dr. Michael Feiz 2Health News:Bayer Agrees To Settle Yaz Aterial Blood Clot Lawsuits 2
... chapping, experts advise , SATURDAY, Dec. 26 (HealthDay News) ... humidity, and the air inside is heated and dry, you ... say. , To prevent scaling, flaking and itching, pay special ... a cream-based moisturizer every day, recommends Dr. Anjali Dahiya, a ...
... Christmas trees and holiday distractions raise risk of a blaze ... on beautifully set tables and yule logs burning make for ... the risk of fires, experts say. , Alcohol and parties ... safety, said Dr. Roger Yurt, director of the Hearst Burn ...
... to those in pot that increase the response to sweets ... some light on the "munchies" -- the desire that pot ... the active ingredient in marijuana, is similar to substances known ... and enhance the perception of sweet foods, researchers say. , ...
... Mouse study holds promise for humans with hereditary disease ... reporting that they,ve discovered a molecular switch that appears ... in mice. , An estimated one out of every ... and disrupts a person,s ability to walk, talk, think ...
... , WASHINGTON, Dec. 24 This ... final passage of HR 3590, the so-called "Patient Protection and ... Research Council President Tony Perkins made the following comments: , ... debate in the Senate, but it,s far from the end ...
... Bill Must Be Improved: Anti-Choice Provisions in Senate and House ... Affordable , WASHINGTON, Dec. 24 The following ... for Women & Families: , "The Senate took a historic ... morning by passing comprehensive reform that will cover 31 million ...
Cached Medicine News:Health News:Skin Needs Protection From Winter Weather 2Health News:Keep Fire Safety in Mind as You Celebrate 2Health News:Scientists Find Molecular Switch Related to Huntington's 2Health News:FRC Statement on the Christmas Eve Passage of the Health Care 'Reform' Bill 2Health News:Senate Passage of Health Reform a Historic Milestone, National Partnership President Says 2
Speculum can be used for any type of eye surgery. Arms of speculum lie flat due to joint between blade and arms. Features quick locking mechanism....
Pediatric model. Spring-controlled spread of blades with locking mechanism. Dull finish. Blades: 11 mm....
Fenestrated blades with screw-controlled spread. Dull finish. Blades: 15 mm....
Designed for use with foster enucleation snare (E3670). Package of 12 stainless steel wires. Overall length 5.3 inches....
Medicine Products: